Just one dose of a newly developed
Zika vaccine gives mice complete immunity to the disease.
Not exact matches
«
Given the key similarities to human infections, a marmoset model of
Zika may be useful for testing of new drug and
vaccines,» said Texas Biomedical Research Institute virologist Jean Patterson, Ph.D. «Having an animal model of
Zika infection to study may help us identify places where we might be able to block transmission.»
Unlike other candidates, a new potential
Zika vaccine is so effective that one shot
gives enough protection — a key advance,
given the virus is here to stay
Col. Nelson Michael, the WRAIR
Zika program co-lead, said, «This critical first step has informed our ongoing work in non-human primates and
gives us early confidence that development of a protective
Zika virus
vaccine for humans is feasible.»
Safety considerations are especially critical,
given that the target population for a
Zika vaccine would likely include men and women of childbearing age.
A
VACCINE against
Zika virus has
given mice and monkeys immunity in tests.
But they will have to
give a
Zika - vaccinated animal dengue to see if the
vaccine makes that illness worse.
This paper showcased research results from the new DNA - based
Zika vaccine that is based on synthetic DNA and
gives instructions to the body's immune system to produce antibodies to attack
Zika antigens (i.e. bacteria, viruses, and other foreign substances that trigger immune responses from the body.)
Researchers
gave a cohort of non-pregnant female mice (n = 20) a 10 µg intramuscular (IM) injection of the
Zika mRNA
vaccine followed by a boost at 28 days.
Ideally, we want a
vaccine that
gives global protection against
Zika strains whether American, Asian or African.
Given the worldwide interest and demand for a
vaccine to curb the dangers the
Zika virus presents, the hope is development will take less than 20 years.